유전자 편집 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Genome Editing Market - Scope of Report

TMR's report on the global genome editing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global genome editing market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global genome editing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the genome editing market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global genome editing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global genome editing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global genome editing market.

The report delves into the competitive landscape of the global genome editing market. Key players operating in the global genome editing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global genome editing market profiled in this report.

Key Questions Answered in Global genome editing market Report:

• What is the sales/revenue generated by wearable injectors across all regions during the forecast period?
• What are the opportunities in the global genome editing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Genome Editing Market - Research Objectives and Research Approach

The comprehensive report on the global genome editing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global genome editing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global genome editing market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Genome Editing Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Genome Editing Market Analysis and Forecasts, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Regulatory Scenario
• 5.2. Technological Advancements
• 5.3. Covid-19 Pandemic Impact on Industry

6. Global Genome Editing Market Analysis and Forecasts, By Technology

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Technology, 2017-2031
  • 6.3.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 6.3.2. Transcription activator-like effector nuclease (TALEN)
  • 6.3.3. Zinc finger nuclease (ZFN)
  • 6.3.4. Other technologies
• 6.4. Market Attractiveness By Technology

7. Global Genome Editing Market Analysis and Forecasts, By Application

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Application, 2017-2031
  • 7.3.1. Cell Line Editing
  • 7.3.2. Animal Genome Editing
  • 7.3.3. Plant Genome Editing
  • 7.3.4. Others
• 7.4. Market Attractiveness By Application

8. Global Genome Editing Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2017-2031
  • 8.3.1. Pharmaceutical Companies and Biotechnology Companies
  • 8.3.2. Academics and Government Research Institutes
  • 8.3.3. Clinical Research Organizations
• 8.4. Market Attractiveness By End-user

9. Global Genome Editing Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America Genome Editing Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Technology, 2017-2031
  • 10.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 10.2.2. Transcription activator-like effector nuclease (TALEN)
  • 10.2.3. Zinc finger nuclease (ZFN)
  • 10.2.4. Other technologies
• 10.3. Market Value Forecast By Application, 2017-2031
  • 10.3.1. Cell Line Editing
  • 10.3.2. Animal Genome Editing
  • 10.3.3. Plant Genome Editing
  • 10.3.4. Others
• 10.4. Market Value Forecast By End-user, 2017-2031
  • 10.4.1. Pharmaceutical Companies and Biotechnology Companies
  • 10.4.2. Academics and Government Research Institutes
  • 10.4.3. Clinical Research Organizations
• 10.5. Market Value Forecast By Country, 2017-2031
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Technology
  • 10.6.2. By Application
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Genome Editing Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Technology, 2017-2031
  • 11.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 11.2.2. Transcription activator-like effector nuclease (TALEN)
  • 11.2.3. Zinc finger nuclease (ZFN)
  • 11.2.4. Other technologies
• 11.3. Market Value Forecast By Application, 2017-2031
  • 11.3.1. Cell Line Editing
  • 11.3.2. Animal Genome Editing
  • 11.3.3. Plant Genome Editing
  • 11.3.4. Others
• 11.4. Market Value Forecast By End-user, 2017-2031
  • 11.4.1. Pharmaceutical Companies and Biotechnology Companies
  • 11.4.2. Academics and Government Research Institutes
  • 11.4.3. Clinical Research Organizations
• 11.5. Market Value Forecast By Country, 2017-2031
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Spain
  • 11.5.5. Italy
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Technology
  • 11.6.2. By Application
  • 11.6.3. By End-user
  • 11.6.4. By Country

12. Asia Pacific Genome Editing Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Technology, 2017-2031
  • 12.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 12.2.2. Transcription activator-like effector nuclease (TALEN)
  • 12.2.3. Zinc finger nuclease (ZFN)
  • 12.2.4. Other technologies
• 12.3. Market Value Forecast By Application, 2017-2031
  • 12.3.1. Cell Line Editing
  • 12.3.2. Animal Genome Editing
  • 12.3.3. Plant Genome Editing
  • 12.3.4. Others
• 12.4. Market Value Forecast By End-user, 2017-2031
  • 12.4.1. Pharmaceutical Companies and Biotechnology Companies
  • 12.4.2. Academics and Government Research Institutes
  • 12.4.3. Clinical Research Organizations
• 12.5. Market Value Forecast By Country, 2017-2031
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Technology
  • 12.6.2. By Application
  • 12.6.3. By End-user
  • 12.6.4. By Country

13. Latin America Genome Editing Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Technology, 2017-2031
  • 13.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 13.2.2. Transcription activator-like effector nuclease (TALEN)
  • 13.2.3. Zinc finger nuclease (ZFN)
  • 13.2.4. Other technologies
• 13.3. Market Value Forecast By Application, 2017-2031
  • 13.3.1. Cell Line Editing
  • 13.3.2. Animal Genome Editing
  • 13.3.3. Plant Genome Editing
  • 13.3.4. Others
• 13.4. Market Value Forecast By End-user, 2017-2031
  • 13.4.1. Pharmaceutical Companies and Biotechnology Companies
  • 13.4.2. Academics and Government Research Institutes
  • 13.4.3. Clinical Research Organizations
• 13.5. Market Value Forecast By Country, 2017-2031
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Technology
  • 13.6.2. By Application
  • 13.6.3. By End-user
  • 13.6.4. By Country

14. Middle East & Africa Genome Editing Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Technology, 2017-2031
  • 14.2.1. Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 14.2.2. Transcription activator-like effector nuclease (TALEN)
  • 14.2.3. Zinc finger nuclease (ZFN)
  • 14.2.4. Other technologies
• 14.3. Market Value Forecast By Application, 2017-2031
  • 14.3.1. Cell Line Editing
  • 14.3.2. Animal Genome Editing
  • 14.3.3. Plant Genome Editing
  • 14.3.4. Others
• 14.4. Market Value Forecast By End-user, 2017-2031
  • 14.4.1. Pharmaceutical Companies and Biotechnology Companies
  • 14.4.2. Academics and Government Research Institutes
  • 14.4.3. Clinical Research Organizations
• 14.5. Market Value Forecast By Country, 2017-2031
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Technology
  • 14.6.2. By Application
  • 14.6.3. By End-user
  • 14.6.4. By Country

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2022)
• 15.3. Company Profiles
  • 15.3.1. Merck KGaA
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. AstraZeneca
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Takara Bio Inc.
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Cellectis SA
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. CRISPR Therapeutics
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Cibus Inc.
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview
  • 15.3.7. RECOMBINETICS
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. SWOT Analysis
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Sangamo Therapeutics
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. SWOT Analysis
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Thermo Fisher Scientific, Inc.
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. SWOT Analysis
    • 15.3.9.5. Strategic Overview